Abbott Laboratories

Medical Devices • Healthcare • North Chicago, IL, United States • ABT (NYQ)

224 667 6100 100 Abbott Park Road, North Chicago, IL 60064-6400, United States

Quarter: Q3 2025 Reported: July 17, 2025

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, hypertriglyceridemia, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also offers laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion serology testing; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; and drug and alcohol test. In addition, the company provides pediatric and adult nutritional products and infant formula; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.

Analysis Summary

The provided earnings announcement for Abbott Laboratories' second quarter 2025, issued on July 17, 2025, does not contain specific financial results such as revenue breakdown by segment, total revenue figures, or any year-over-year growth percentages. Instead, the document focuses entirely on the company's methodology for presenting non-GAAP financial measures, directing readers to Exhibit 99.1 for the actual operational results. Therefore, a detailed analysis of revenue performance across Abbott's various business segments cannot be conducted from this release.

Similarly, profitability metrics, including net income, earnings per share (EPS), or operational efficiency ratios, are not disclosed within this announcement. The text explains that non-GAAP measures exclude factors like intangible amortization, acquisition-related expenses, restructuring costs, and certain regulatory costs to offer greater visibility into ongoing business performance. While this provides insight into Abbott's reporting philosophy, it does not offer the quantitative data necessary to assess the company's financial health or operational efficiency for the quarter.

Strategic initiatives, management commentary on performance, or any forward-looking statements are absent from this announcement. The document's sole focus is on the definition and rationale behind Abbott's non-GAAP financial reporting. Management believes these non-GAAP measures are useful for investors and for internal performance monitoring, but no specific strategic updates or insights into the company's direction are provided.

Given the lack of specific financial results, including revenue, earnings, and segment performance, no forward guidance for the upcoming quarter or the full year can be extracted from this announcement. The market positioning or future outlook for Abbott Laboratories cannot be assessed based on the information provided, as the release serves primarily as a disclosure regarding non-GAAP financial reporting practices rather than a comprehensive earnings report.

Key Highlights

• Announcement pertains to Q2 2025 results, not Q3 2025 as initially requested in the prompt.
• Specific financial results (revenue, net income, EPS) are not provided in the announcement.
• The announcement primarily discusses the use and rationale of non-GAAP financial measures.
• Actual operational results are referenced as being furnished in Exhibit 99.1.
• Non-GAAP measures adjust for unusual or unpredictable factors like acquisition expenses and restructuring.
• Management uses non-GAAP measures internally to monitor business performance.
• Investors are cautioned to consider non-GAAP measures in addition to, not as a substitute for, GAAP measures.

Financial Metrics

eps

revenue

guidance

net income

Stock Performance (90 Days)

Data through Dec 30, 2025

Layoff Events

Earnings Calls

Positive Signals

• Specific financial data for Q2 2025 is not available in the provided text.
• No management commentary on performance or outlook is included.
• Reliance on external Exhibit 99.1 for actual results.
• Focus solely on non-GAAP reporting methodology.

Risks & Concerns

— Lack of immediate transparency on financial performance in the provided document.
— Potential for misinterpretation if investors do not review the full Exhibit 99.1.
— Reliance on non-GAAP measures might obscure certain underlying financial trends if not properly reconciled with GAAP.